Robert Bessler Sells 5,101 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 5,101 shares of the stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $7.01, for a total transaction of $35,758.01. Following the transaction, the director owned 1,309,397 shares of the company’s stock, valued at $9,178,872.97. This represents a 0.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

LifeStance Health Group Stock Performance

NASDAQ:LFST traded up $0.08 on Thursday, reaching $6.99. 1,213,360 shares of the company’s stock were exchanged, compared to its average volume of 2,067,154. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.65 and a quick ratio of 1.65. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of 349.67 and a beta of 1.13. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.09. The stock has a fifty day simple moving average of $6.73 and a 200-day simple moving average of $6.53.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The business had revenue of $382.20 million for the quarter, compared to the consensus estimate of $378.51 million. LifeStance Health Group had a return on equity of 0.65% and a net margin of 0.68%.LifeStance Health Group’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.01) EPS. As a group, sell-side analysts predict that LifeStance Health Group, Inc. will post 0.09 earnings per share for the current year.

LifeStance Health Group declared that its Board of Directors has authorized a share repurchase program on Wednesday, February 25th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to buy up to 3.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Hedge Funds Weigh In On LifeStance Health Group

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after acquiring an additional 3,086,506 shares during the period. Silversmith Partners I GP LLC bought a new position in shares of LifeStance Health Group in the fourth quarter valued at approximately $100,842,000. Dimensional Fund Advisors LP raised its stake in LifeStance Health Group by 6.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 8,906,465 shares of the company’s stock valued at $62,704,000 after purchasing an additional 542,858 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in LifeStance Health Group by 27.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock valued at $43,071,000 after purchasing an additional 1,324,691 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after buying an additional 1,839,465 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LFST has been the subject of a number of analyst reports. Jefferies Financial Group upgraded shares of LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th. Wall Street Zen upgraded shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Canaccord Genuity Group raised their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. KeyCorp raised their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings upgraded shares of LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, LifeStance Health Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.83.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.